No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - Creo Medical said on Monday that first-quarter revenue rose about 60% year on year, at the upper end of management expectations, driven by customer adoption, higher procedure volumes and conversion of its commercial pipeline.
The AIM-traded medical device group now expects FY26 revenue growth of 50% to 60%, narrowed from previous guidance of 40% to 60%, and said recent updates on Speedboat, SpydrBlade Flex and MicroBlate Fine showed broader clinical and commercial traction.
Creo said it remained focused on efficiency after the sale and outsourcing of manufacturing, expected to cut annual operating costs by more than 1.0m, while a 5.5m placing and 2.0m convertible loan note subscription from the Development Bank of Wales would support inventory, customer roll-out and expansion.
At 1334 BST, shares in Creo Medical Group were up 8.89% at 14.7p.
Reporting by Josh White for Sharecast.com.
See latest RNS on Investegate
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.